Drug Profile
PF 06842433
Alternative Names: PF-06842433Latest Information Update: 17 Aug 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pneumococcal infections
Most Recent Events
- 02 May 2023 Discontinued - Phase-II for Pneumococcal infections (In children, In infants, Prevention) in USA (unspecified route) (Pfizer pipeline, August 2023)
- 06 Jan 2023 PF 06842433 is still in phase II trials for Pneumococcal infections (Prevention, In infants, In children) in USA (unspecified route) (Pfizer pipeline, November 2022)
- 01 Dec 2020 PF 06842433 is still in phase II trials for Pneumococcal infections (Prevention, In infants, In children) in USA (unspecified route) (Pfizer pipeline, December 2020)